Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...4647484950515253545556...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Sep 8, 2019   
    P3
    Baseline subretinal fluid absence, intraretinal cyst presence, and fellow eye atrophy presence were associated with month 24 MA presence. With existing data, the benefits of ranibizumab for neovascular AMD outweighed the risk of MA development over 24 months in HARBOR, although outcomes >2 years were not evaluated.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Optical Coherence Tomography Angiography-based Follow-up Observation of Wet Age-related Macular Degeneration after Intravitreal Anti-Ranibizumab Therapy (Pubmed Central) -  Sep 7, 2019   
    Despite having worse vision/increased CST versus those without baseline MNP, eyes with concurrent DME and baseline MNP entering RIDE/RISE experienced robust VA and anatomic improvement with ranibizumab and therefore should not be excluded from therapy. Objective To observe the imaging features of optical coherence tomography angiography(OCTA)in eyes with wet age-related macular degeneration(wAMD)after treatment with 3+pro re nata(3+PRN)of intravitreal anti-Ranibizumab.Methods This study included 8 treatment-naive eyes with wAMD diagnosed by fluorescein fundus angiography(FFA)and indocyanine green angiography(ICGA)from September 2016 to May 2017.All the patients were treated with 3+PRN of intravitreal anti-Ranibizumab(0.5 mg/0.05 ml).We performed OCTA with 6 mm×6 mm scans at baseline and 1,3,and 6 months after treatment.We analyzed best corrected visual acuity(BCVA)(logMAR),type of choroidal neovascular(CNV),and morphological features and changes of CNV,central retinal thickness(CRT),outer retina vessel density(ORVD),and choroidal capillary vessel density(CCVD).Results A total of 8 eyes were examined in 8 patients[4 males and 4 females with a mean age of(70.9±10.6)years of age].Three eyes had type Ⅰ CNV and 5 eyes had type Ⅱ CNV.At baseline,month 1,month 3,and month 6,BCVA was 0.55(0.33,0.87),0.35(0.24,0.84),0.35(0.22,0.58),and 0.26(0.10,0.58)logMAR,respectively(all P>0.05).CRT was(271.88±91.95),(204.00±45.78),(196.00±31.14),and(219.25±71.32)μm,respectively,and there was a statistical significance between CRT at baseline and CRT at month 3(t=2.211,P=0.044).ORVD was(41.38±2.77)%,(41.73±3.60)%,(42.53±1.95)%,and(41.40±2.33)%,respectively(all P>0.05).CCVD was(64.38±2.24)%,(64.96±1.39)%,(64.16±1.39)%,and(64.63±1.86)%,respectively(all P>0.05).Correlation analysis showed BCVA was significantly correlated with both CRT(P=0.009, RR=0.457)and CCVD(P=0.001,RR=0.574),but not with ORVD(P=0.093,RR=0.302).The morphological features at baseline showed that 2 eyes were lump-like,2 eyes were line-like,2 eyes were tangles,1 eye was elliptical ring-like,and 1 eye was fragment.At month 1,the morphologies were improved in 7 eyes,including the CNV showed decreased maximum diameter,rupture/fragment,loss of peripheral capillaries,decreased numbers and density,and reduced maximum cross-sectional area;the condition became worse in 1 eye,including the CNV showed ring formation,increased density,and increased maximum diameter.At month 3,the morphologied of 7 eyes were improved,while no obvious change was seen in 1 eye.At month 6,the CNV became normalized in 5 eyes but worsened in 3 eyes.No intraocular infection or other intravitreal injection-related complication was observed during the follow-up.Conclusion Observing CNV characteristics using OCTA technology can be used to evaluate the efficacy of Ranibizumab in patients with wAMD and guide the treatment and follow-up of wAMD patients.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  The impact of central foveal thickness on the efficacy of subthreshold micropulse yellow laser photocoagulation in diabetic macular edema. (Pubmed Central) -  Sep 6, 2019   
    ...Eighty eyes of 40 patients who had previously undergone ranibizumab treatment for DME and who subsequently had recurrent macular edema were included to the study...Hyperautofluorescence lesions, that were not previously described, were detected in fundus autofluorescence imaging in the early period after SYMLP laser and these lesions were regressed with time. Our study indicates that the SYMLP provides a statistically significant improvement in BCVA and a reduction in CFT in the patients with a pretreatment CFT of 300 μm or less in DME and can be safe and effective in mild DME treatment.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema. (Pubmed Central) -  Sep 6, 2019   
    Both groups had significant improvement in contrast sensitivity and mean deviation on visual fields; however, the difference between the groups was not significant (P = 0.62 and P = 0.79, respectively). UWFFA-guided TRP reduced the number of injections of Ranibizumab in patients having BRVO with macular edema, while maintaining similar benefits in the improvement of BCVA, central subfoveal thickness without deleterious effect on the visual field, and contrast sensitivity.
  • ||||||||||  faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Diabetic Retinopathy Improvements With Intravitreal Faricimab in the Phase 2 BOULEVARD Trial (Moscone Center EPOSTER & VIDEO TERMINALS) -  Sep 5, 2019 - Abstract #AAO2019AAO_2560;    
    P2
    There was no notable difference in proportion of PT patients with ≥ 2-step improvement between treatment arms. Conclusion Among TN patients, a higher proportion of faricimab-treated patients achieved ≥2-step DR severity improvement, suggesting a potential benefit of simultaneous angiopoietin-2 and VEGF-A neutralization by faricimab in DME and DR.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Can Early Intervention Reduce the Need for Invasive Management of Diabetic Retinopathy? (Moscone Center EPOSTER & VIDEO TERMINALS) -  Sep 5, 2019 - Abstract #AAO2019AAO_2559;    
    P3
    Purpose To assess the effect of early ranibizumab (RBZ) therapy on rates of panretinal photocoagulation (PRP), vitreous hemorrhage (VH) and vitrectomy events in patients with diabetic retinopathy (DR)...In RBZ-treated patients with and without ≥2-step DR improvement, the rate of any event was lower in those with NPDR (2.8% and 3.7%, respectively) than PDR (14.3% and 8.0%, respectively). Conclusion Initiating RBZ before PDR was associated with fewer PRP, VH and vitrectomy events in RIDE and RISE.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    High-Dose Anti-VEGF: Cross-Trial Analysis of Different Doses and Antagonists for the Treatment of DME (Moscone Center EPOSTER & VIDEO TERMINALS) -  Sep 5, 2019 - Abstract #AAO2019AAO_2557;    
    P2, P3
    Results Within four trials of ranibizumab (RBZ) and one trial of aflibercept (AFL), there was no consistent benefit from higher- versus lower-dose anti-VEGF...Conclusion Across trials, anti-VEGF treatment resulted in meaningful improvements in patients with DME regardless of dose. Within trials, doubling or quadrupling doses did not seem to provide additional benefits.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Timing of Peak Vision Gains Is Associated With Greater 24-Month Visual Outcomes: A Post Hoc Analysis of HARBOR (Moscone Center EPOSTER & VIDEO TERMINALS) -  Sep 5, 2019 - Abstract #AAO2019AAO_2545;    
    P3
    Purpose This post hoc analysis of HARBOR (NCT00891735) identified the time of peak vision gain of patients treated with ranibizumab (RBZ) for neovascular AMD (nAMD)...or monthly dosing. The month-24 visual outcomes are dramatically different (nearly four lines of vision) between these groups.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Association Between Early Visual Function Outcomes and Anatomic Dryness in nAMD (Moscone Center EPOSTER & VIDEO TERMINALS) -  Sep 5, 2019 - Abstract #AAO2019AAO_2544;    
    Results More patients were PD with intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4; 188, 30.7%) and IAI every 8 wks (2q8; 182, 30.0%) than ranibizumab every 4 weeks (Rq4, 141, 23.7%; P < .05 for both) at week 12...Within-group letter difference (95% CI) in BCVA gains for PD versus NPD with IRF was 3.4 (1.6, 5.2) for Rq4, −0.3 (−2.1, 1.5) for 2q4 and 2.2 (0.1, 4.3) for 2q8 at week 24. Conclusion AMD patients with IRF early in treatment sustain lower BCVA gains.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Real-World Outcomes in nAMD: Eight Years of 44,304 Ranibizumab Injections (Moscone Center EPOSTER & VIDEO TERMINALS) -  Sep 5, 2019 - Abstract #AAO2019AAO_2543;    
    Conclusion Real-world visual outcomes compare to recent studies in practice. Most improvement with ranibizumab is seen initially, followed by slow decline.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Efficacy of the T&E Regimen in the Management of nAMD: Five-Year Results of the RENO Study (Moscone Center EPOSTER & VIDEO TERMINALS) -  Sep 5, 2019 - Abstract #AAO2019AAO_2530;    
    At final follow-up, 17.0% lost ≥15 letters, and 30.3% of eyes had gained ≥15 letters. Conclusion The T&E regimen improved vision for up to 5 years in nAMD patients receiving ≥6 injections in year 1.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Geographic Atrophy in Patients Receiving Anti-VEGF Treatment for nAMD (Moscone Center EPOSTER & VIDEO TERMINALS) -  Sep 5, 2019 - Abstract #AAO2019AAO_2520;    
    Conclusion Treating nAMD with aflibercept, bevacizumab or ranibizumab demonstrated comparable GA development at 24 months. Number of injections inversely correlated with GA area and growth.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Evolution of Polypoidal Lesions Among Patients of a Multicenter Randomized Controlled Clinical Trial on Polypoidal Choroidal Vasculopathy (Moscone Center EPOSTER & VIDEO TERMINALS) -  Sep 5, 2019 - Abstract #AAO2019AAO_2515;    
    Results Complete polyp regression was significantly higher among patients treated with combination photodynamic therapy and ranibizumab compared to ranibizumab monotherapy (80% versus 35.7% at month 12; P = .016)...New polyps were more frequent from month 6 and progressively formed a larger proportion of all polyps over the course of treatment. Conclusion Polyp evolution varies significantly during treatment, with most new polyps developing from month 6.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Update on Treatments for Diabetic Retinopathy: Clinically Relevant Results From the DRCR.net (Moscone Center WEST 2008) -  Sep 5, 2019 - Abstract #AAO2019AAO_1288;    
    In addition, the attendee will learn clinically relevant secondary results from a study evaluating the comparative effectiveness of aflibercept, bevacizumab or ranibizumab for diabetic macular edema and the comparative effectiveness of panretinal photocoagulation with anti-VEGF treatment for proliferative diabetic retinopathy. Finally, the attendee will be able to apply the DRCR.net results to clinically relevant situations in daily practice.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2. (Pubmed Central) -  Aug 30, 2019   
    The in vivo pharmacological studies demonstrated that the incidence of CNV formation was largely reduced in RC28 treatment groups with a low dosage as compared to other VEGF antagonist control groups. Furthermore, traces of RC28 were detected as dispersing from eyeballs to the liver after 20 days, and a prolonged half-time pharmacokinetic profile was exhibited.
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal, Adverse events:  Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016. (Pubmed Central) -  Aug 29, 2019   
    Endophthalmitis (OR 6.96, 95% CI 2.74-17.73) was more likely to be reported in patients with aflibercept than in patients without aflibercept, whereas medicine ineffective (OR 18.49, 95% CI 2.39-143.29) and retinal disorder (OR 7.03, 95% CI 1.60-30.96) were more likely to be reported in patients with ranibizumab than in patients without ranibizumab.New signals have been identified for aflibercept and ranibizumab. Further research is necessary to evaluate the causality of AEs that were detected as signals in this study.
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
    New P4 trial, Monotherapy:  Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov) -  Aug 29, 2019   
    P4,  N=150, Not yet recruiting, 
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Optimization of the port delivery system with ranibizumab (PDS) implant insertion procedure in the ladder phase 2 trial (Room 241 (Level 2)) -  Aug 28, 2019 - Abstract #EURETINA2019EURETINA_27;    
    P2, P3
    The optimized PDS implant insertion procedure with laser ablation of the pars plana at the incision site reduced the vitreous hemorrhage rate in the Ladder trial when standardized surgical steps were strictly followed. A robust training plan has been implemented for the ongoing phase 3 Archway trial (NCT03677934) to ensure procedural consistency and prioritize patient safety.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Analysis of the relationship between anatomic control and visual acuity outcomes with anti-VEGF therapy: a post-hoc analysis of catt study data (Amphitheatre Havane) -  Aug 28, 2019 - Abstract #EURETINA2019EURETINA_24;    
    The findings suggest that prolonged exposure to excess macular fluid during the first year of anti-VEGF treatment, as signified by a higher cumulative average central retinal thickness with an IRF component or a greater proportion of time with IRF present, results in sub-optimal BCVA improvement, after controlling for age, gender, baseline BCVA and retinal thickness. The ability to achieve and sustain a dry retina and adhere to a treatment regimen that provides consistent anatomic control remain key treatment considerations in nAMD.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Complex assessment of retinal ischemic damage in patients with retinal vein occlusion (Pubmed Central) -  Aug 23, 2019   
    Determination of the degree of macular ischemia at the stage of primary diagnosis can improve the treatment effectiveness and inform the patients about the sequence and duration of anti-VEGF therapy. Intravitreal injections of ranibizumab in retinal vein occlusion are carried out before the elimination of macular edema and further in the on-demand mode, while the number of injections can vary from one to monthly injections during the year.